Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials


Amirhossein Sahebkar | Kazuhiko Kotani | Corina Serban | Sorin Ursoniu | Dimitri P. Mikhailidis | Steven R. Jones | Kausik K. Ray | Michael J. Blaha | Jacek Rysz | Peter P. Toth | Paul Muntner | Gregory Y.H. Lip | Maciej Banach | Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group



Raised plasma endothelin-1 (ET-1) levels may be a risk factor for vascular dysfunction and cardiovascular (CV) disease. This meta-analysis assessed the effect of statins on circulating ET-1 concentrations.

Methods and results

The search included PUBMED, Cochrane Library, Web of Science, Scopus, and EMBASE up to September 30, 2014 to identify randomized controlled trials (RCTs) with ET-1 measurement during statin therapy. Quantitative data synthesis was performed using a random-effects model, with weighed mean difference (WMD) and 95% confidence interval (CI) as summary statistics. Data from 15 RCTs showed that statin therapy significantly reduces plasma ET-1 concentrations (WMD: −0.30 pg/mL, 95%CI: −0.47, −0.13; p < 0.01). This effect was robust in sensitivity analysis, and not largely affected by the duration of statin therapy (<12 weeks – WMD: −0.51 pg/mL, 95%CI: −0.89, −0.14, p < 0.01; >12 week –WMD: −0.19 pg/mL, 95%CI: −0.36, −0.02; p < 0.05) or by dose of statins (<40 mg/day – WMD: −0.27 pg/mL, 95%CI: −0.49, −0.05; p = 0.01; >40 mg/day – WMD: −0.38 pg/mL, 95%CI: −0.68, −0.08; p = 0.01). Lipophilic (atorvastatin, simvastatin, fluvastatin, and cerivastatin – WMD: −0.34 pg/mL, 95%CI: −0.55, −0.13; p < 0.01), but not a hydrophilic statin (pravastatin – WMD: −0.18 pg/mL, 95%CI: −0.44 −0.08; p > 0.05) had a significant effect in promoting ET-1 reduction.


Statin therapy significantly reduces circulating ET-1 concentrations, regardless of treatment duration or dose of statins. This effect of statins may be influenced by statin lipophilicity. There is a need to establish whether lowering ET-1 levels has a beneficial effect on CV events.

  1. Negi S., Anand A.
    Atherosclerotic coronary heart disease epidemiology, classification and management.
    Cardiovasc. Haematol. Disorders-Drug Targets (Formerly Curr. Drug Targets-Cardiovasc. Hematol. Disord. 2010; 10: 257-261
  2. Mordi I. ,Tzemos N.
    Is reversal of endothelial dysfunction still an attractive target in modern cardiology?.
    World J. Cardiol. 2014; 6: 824
  3. Piechota M., Banach M., Jacoń A., et al.
    Natriuretic peptides in cardiovascular diseases.
    Cell. Mol. Biol. Lett. 2008; 13: 155-181
  4. Förstermann U.
    Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies.
    Nat. Clin. Pract. Cardiovasc. Med. 2008; 5: 338-349
  5. Pernow J., Shemyakin A., Böhm F.
    New perspectives on endothelin-1 in atherosclerosis and diabetes mellitus.
    Life Sci. 2012; 91: 507-516
  6. Yanagisawa M., Kurihara H., Kimura S., et al.
    A novel potent vasoconstrictor peptide produced by vascular endothelial cells.
    Nature. 1988; 332: 411-415
  7. Shimada K., Takahashi M., Tanzawa K.
    Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells.
    J. Biol. Chem. 1994; 269: 18275-18278
  8. Irzmanski R., Banach M., Piechota M., et al.
    Atrial and brain natriuretic peptide and endothelin-1 concentration in patients with idiopathic arterial hypertension: the dependence on the selected morphological parameters.
    Clin. Exp. Hypertens. 2007; 29: 149-164
  9. Lavie L.
    Obstructive sleep apnoea syndrome–an oxidative stress disorder.
    Sleep. Med. Rev. 2003; 7: 35-51
  10. Jagroop I.A., Daskalopoulou S.S., Mikhailidis D.P.
    Endothelin-1 and human platelets.
    Curr. Vasc. Pharmacol. 2005; 3: 393-399
  11. Morawietz H., Duerrschmidt N., Niemann B., et al.
    Induction of the oxLDL receptor LOX-1 by endothelin-1 in human endothelial cells.
    Biochem. Biophys. Res. Commun. 2001; 284: 961-965
  12. Meyers K.E., Sethna C.
    Endothelin antagonists in hypertension and kidney disease.
    Pediatr. Nephrol. 2013; 28: 711-720
  13. Schaefer R.
    Lipid management for the prevention of cardiovascular disease.
    Curr. Pharm. Des. 2011; 17: 852-860
  14. Toth P.P.
    Low-density lipoprotein reduction in high-risk patients: how low do you go?.
    Curr. Atheroscler. Rep. 2004; 6: 348-352
  15. Banach M., Mikhailidis D.P., Kjeldsen S.E., et al.
    Time for new indications for statins?.
    Med. Sci. Monit. 2009; 15: MS1-MS5
  16. Banach M., Aronow W.S., Serban C., et al.
    Lipids, blood pressure and kidney update 2014.
    Pharmacol. Res. 2015; 95: 111-125
  17. Ii M., Losordo D.W.
    Statins and the endothelium.
    Vasc. Pharmacol. 2007; 46: 1-9
  18. Blum A., Shamburek R.
    The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis.
    Atherosclerosis. 2009; 203: 325-330
  19. Sahebkar A., Chew G.T., Watts G.F.
    Recent advances in pharmacotherapy for hypertriglyceridemia.
    Prog. Lipid Res. 2014; 56: 47-66
  20. Hernández-Perera O., Pérez-Sala D., Navarro-Antolín J., et al.
    Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.
    J. Clin. Investig. 1998; 101: 2711
  21. Moher D., Liberati A., Tetzlaff J., et al.
    Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
    BMJ. 2009; 339: b2535
  22. Jadad A.R., Moore R.A., Carroll D., et al.
    Assessing the quality of reports of randomized clinical trials: is blinding necessary?.
    Control. Clin. Trials. 1996; 17: 1-12
  23. Moher D., Cook D., Jadad A., et al.
    Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses.
    Health Technol. Assess. Winch. Engl. 1998; 3 (1–98): i-iv
  24. Borenstein M., Hedges L., Higgins J., et al.
    Comprehensive Meta-analysis Version 2.
    Biostat, Englewood, NJ2005 (104–104)
  25. Sutton A.J., Abrams K.R., Jones D.R., et al.
    Methods for Meta-analysis in Medical Research.
    J. Wiley, 2000
  26. Sahebkar A.
    Does PPARγ2 gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis.
    DNA Cell Biol. 2013; 32: 188-198
  27. Dupont W.D., Plummer W.D.
    Power and sample size calculations for studies involving linear regression.
    Control. Clin. Trials. 1998; 19: 589-601
  28. Song F., Altman D.G., Glenny A.-M., et al.
    Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses.
    Bmj. 2003; 326: 472
  29. Bucher H.C., Guyatt G.H., Griffith L.E., et al.
    The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials.
    J. Clin. Epidemiol. 1997; 50: 683-691
  30. Duval S., Tweedie R.
    Trim and fill: a simple funnel-plot–based method of testing and adjusting for publication bias in meta-analysis.
    Biometrics. 2000; 56: 455-463
  31. Abou-Raya A. ,Abou-Raya S., Helmii M.
    Statins as immunomodulators in systemic sclerosis.
    Ann. N. Y. Acad. Sci. 2007; 1110: 670-680
  32. Åsberg A., Holdaas H., Jardine A.G., et al.
    Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation.
    Clin. Transplant. 2003; 17: 385-390
  33. Barsuk A.L., VAM, Malinok E.V., Lovtsova L.V., Okrut I.E., Kuzin V.B.
    The dynamics and interaction of endothelium state and immune status variations in program hemodialysis patients against the background of atorvastatin therapy.
    Mod. Thechnol. Med. 2013; 5: 78-83
  34. Dupuis J., Tardif J.-C., Cernacek P., et al.
    Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes the RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial.
    Circulation. 1999; 99: 3227-3233
  35. Glorioso N., Troffa C., Filigheddu F., et al.
    Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia.
    Hypertension. 1999; 34: 1281-1286
  36. Lee T.-M., Su S.-F., Tsai C.-H.
    Effect of pravastatin on proteinuria in patients with well-controlled hypertension.
    Hypertension. 2002; 40: 67-73
  37. Lee T., Chen C., Shen H., et al.
    Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension.
    Clin. Sci. 2009; 116: 497-505
  38. Lee T.-M., Lin M.-S., Tsai C.-H., et al.
    Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT1 receptor blockers.
    Kidney Int. 2005; 68: 779-787
  39. Lewandowski J.,  Siński M., Bidiuk J., et al.
    Simvastatin reduces sympathetic activity in men with hypertension and hypercholesterolemia.
    Hypertens. Res. 2010; 33: 1038-1043
  40. Li J.-J., Fang C.-H., Wang C., et al.
    Effects of simvastatin on exercise-induced myocardial ischemia and plasma endothelin-1 concentrations in patients with stable angina.
    Clin. Chim. acta. 2005; 354: 205-208
  41. Nakamura T., Ushiyama C., Hirokawa K., et al.
    Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia.
    Am. J. Nephrol. 2001; 21: 449-454
  42. Mozaffarian D., Minami E., Letterer R.A., et al.
    The effects of atorvastatin (10 mg) on systemic inflammation in heart failure.
    Am. J. Cardiol. 2005; 96: 1699-1704
  43. Tehrani S., Mobarrez F., Lins P.-E., et al.
    Impaired endothelium-dependent skin microvascular function during high-dose atorvastatin treatment in patients with type 1 diabetes.
    Diabetes Vasc. Dis. Res. 2013; 10: 483-488
  44. Usharani P., Mateen A.A., Naidu M.U.R., et al.
    Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus.
    Drugs R. D. 2008; 9: 243-250
  45. Economides P.A., Caselli A., Tiani E., et al.
    The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes.
    J. Clin. Endocrinol. Metabol. 2004; 89: 740-747
  46. Usharani P., Mateen A., Naidu M., et al.
    Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus.
    Drugs R. D. 2008; 9: 243-250
  47. Tanner F.C., Boulanger C.M., Lüscher T.F.
    Endothelium-derived nitric oxide, endothelin, and platelet vessel wall interaction: alterations in hypercholesterolemia and atherosclerosis.
    Seminars Thromb. Hemost. 1992; : 167-175
  48. Ludman A., Venugopal V., Yellon D.M., et al.
    Statins and cardioprotection—more than just lipid lowering?.
    Pharmacol. Ther. 2009; 122: 30-43
  49. Mihos C.G., Pineda A.M., Santana O.
    Cardiovascular effects of statins, beyond lipid-lowering properties.
    Pharmacol. Res. 2014; 88: 12-19
  50. Kohan D.E.
    Endothelins in the normal and diseased kidney.
    Am. J. Kidney Dis. 1997; 29: 2-26
  51. Battistini B., D’Orleans-Juste P., Sirois P.
    Endothelins: circulating plasma levels and presence in other biologic fluids.
    Lab. Investig. J. Tech. Methods Pathol. 1993; 68: 600
  52. Krum H., Ashton E., Reid C., et al.
    Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.
    J. Card. Fail. 2007; 13: 1-7
  53. Qu H.Y., Xiao Y.W., Jiang G.H., et al.
    Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia.
    Pharm. Res. 2009; 26: 958-964
  54. Sakamoto T., Kojima S., Ogawa H., et al.
    Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: subanalysis of MUSASHI-AMI.
    Circ. J. Off. J. Jpn. Circ. Soc. 2007; 71: 1348-1353
  55. Fujita M., Yamazaki T., Hayashi D., et al.
    Pleiotropic effects of statins on cardiovascular events in the Japanese coronary artery disease study.
    Int. J. Cardiol. 2008; 129: 294-296
  56. Kai T., Arima S., Taniyama Y., et al.
    Comparison of the effect of lipophilic and hydrophilic statins on serum adiponectin levels in patients with mild hypertension and dyslipidemia: Kinki adiponectin interventional (KAI) Study.
    Clin. Exp. Hypertens. 2008; 30: 530-540
  57. Tsutamoto T., Yamaji M., Kawahara C., et al.
    Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with non-ischaemic chronic heart failure.
    Eur. J. heart Fail. 2009; 11: 1195-1201
  58. Kim M.C., Ahn Y., Jang S.Y., et al.
    Comparison of clinical outcomes of hydrophilic and lipophilic statins in patients with acute myocardial infarction.
    Korean J. Intern. Med. 2011; 26: 294-303
  59. Murrow J.R., Sher S., Ali S., et al.
    The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin.
    J. Clin. Lipidol. 2012; 6: 42-49
  60. Bailey K.M., Romaine S.P., Jackson B.M., et al.
    Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 study.
    Circ. Cardiovasc Genet. 2010; 3: 276-285
  61. Mason R.P., Walter M.F., Day C.A., et al.
    Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
    Am. J. Cardiol. 2005; 96: 11-23
  62. Tomizawa A., Hattori Y., Suzuki K., et al.
    Effects of statins on vascular endothelial function in hypercholesterolemic patients with type 2 diabetes mellitus: fluvastatin vs. rosuvastatin.
    Int. J. Cardiol. 2010; 144: 108-109
  63. Nezasa K., Higaki K., Matsumura T., et al.
    Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin.
    Drug Metab. Dispos. 2002; 30: 1158-1163
  64. Liu G., Zheng X.-X, Xu Y.-L., et al.
    Effects of lipophilic statins for heart failure: a meta-analysis of 13 randomised controlled trials.
    Heart, Lung Circulation. 2014; 23: 970-977
  65. Sahebkar A., Watts G.F.
    New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Clin. Ther. 2013; 35: 1082-1098
  66. Dragan S., Serban M.-C., Banach M.
    Proprotein convertase Subtilisin/Kexin 9 inhibitors an emerging lipid-lowering therapy?.
    J. Cardiovasc. Pharmacol. Ther. 2015; 20: 157-168